Abstract
Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are driver mutations in acute myeloid leukemia (AML) and other cancers. We report the development of new allosteric inhibitors of mutant IDH1. Crystallographic and biochemical results demonstrated that compounds of this chemical series bind to an allosteric site and lock the enzyme in a catalytically inactive conformation, thereby enabling inhibition of different clinically relevant IDH1 mutants. Treatment of IDH1 mutant primary AML cells uniformly led to a decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells, in vitro and in vivo. Molecularly, treatment with the inhibitors led to a reversal of the DNA cytosine hypermethylation patterns caused by mutant IDH1 in the cells of individuals with AML. Our study provides proof of concept for the molecular and biological activity of novel allosteric inhibitors for targeting different mutant forms of IDH1 in leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rakheja, D., Konoplev, S., Medeiros, L.J. & Chen, W. IDH mutations in acute myeloid leukemia. Hum. Pathol. 43, 1541–1551 (2012).
Gupta, R. et al. Expanding the spectrum of IDH1 mutations in gliomas. Mod. Pathol. 26, 619–625 (2013).
Luchman, H.A. et al. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-oncology 14, 184–191 (2012).
Ward, P.S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y. & Yamazaki, N. Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 178, 1395–1402 (2011).
Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
Sasaki, M. et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488, 656–659 (2012).
Schulze, A. & Harris, A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364–373 (2012).
Shih, A.H., Abdel-Wahab, O., Patel, J.P. & Levine, R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat. Rev. Cancer 12, 599–612 (2012).
Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).
Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).
Figueroa, M.E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).
Losman, J.A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
Ye, D., Ma, S., Xiong, Y. & Guan, K.L. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 23, 274–276 (2013).
Kuendgen, A. & Germing, U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat. Rev. 35, 97–120 (2009).
Burnett, A.K. Treatment of acute myeloid leukemia: are we making progress? Hematology (Am. Soc. Hematol. Educ. Program) 2012, 1–6 (2012).
Abdel-Wahab, O., Patel, J. & Levine, R.L. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol. Oncol. Clin. North Am. 25, 1119–1133 (2011).
Molenaar, R.J., Radivoyevitch, T., Maciejewski, J.P., van Noorden, C.J. & Bleeker, F.E. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim. Biophys. Acta 1846, 326–341 (2014).
Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013).
Wang, F. et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340, 622–626 (2013).
Yen, K. et al. AG-221 offers a survival advantage in a primary human IDH2 mutant AML xenograft model (American Society of Hematology Annual Meeting and Exposition abstract). Blood 122, 240 (2013).
Xu, X. et al. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J. Biol. Chem. 279, 33946–33957 (2004).
Deng, G. et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J. Biol. Chem. 290, 762–774 (2015).
Yang, B., Zhong, C., Peng, Y., Lai, Z. & Ding, J. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Res. 20, 1188–1200 (2010).
Rendina, A.R. et al. Mutant IDH1 enhances the production of 2-hydroxyglutarate due to its kinetic mechanism. Biochemistry 52, 4563–4577 (2013).
van Westen, G.J., Gaulton, A. & Overington, J.P. Chemical, target, and bioactive properties of allosteric modulation. PLOS Comput. Biol. 10, e1003559 (2014).
McCarthy, N.C., Albrechtsen, M.T. & Kerr, M.A. Characterization of a human granulocyte differentiation antigen (CDw15) commonly recognized by monoclonal antibodies. Biosci. Rep. 5, 933–941 (1985).
Lacombe, F. et al. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11, 1878–1886 (1997).
Sandes, A.F. et al. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry B Clin. Cytom. 84, 157–166 (2013).
Tenen, D.G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 3, 89–101 (2003).
Pandolfi, A., Barreyro, L. & Steidl, U. Concise review: Preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Transl. Med. 2, 143–150 (2013).
Will, B. et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nat. Med. 21, 1172–1181 (2015).
Cohen, A.L., Holmen, S.L. & Colman, H. IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep. 13, 345 (2013).
Lu, C. et al. Induction of sarcomas by mutant IDH2. Genes Dev. 27, 1986–1998 (2013).
Zheng, B. et al. Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase. ACS Med. Chem. Lett. 4, 542–546 (2013).
Davis, M.I. et al. Biochemical, cellular and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J. Biol. Chem. 289, 13717–13725 (2014).
Brooks, E. et al. Identification and characterization of small-molecule inhibitors of the R132H/R132H mutant isocitrate dehydrogenase 1 homodimer and R132H/wild-type heterodimer. J. Biomol. Screen. 19, 1193–1200 (2014).
Chen, S.J. et al. Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. Blood 78, 2696–2701 (1991).
Tallman, M.S. et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337, 1021–1028 (1997).
Kats, L.M. et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 14, 329–341 (2014).
Duncan, C.G. et al. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 22, 2339–2355 (2012).
Copeland, R.A. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem. Anal. 46, 1–265 (2005).
Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044 (2007).
Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255–265 (2011).
Kruse, U. et al. Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89–100 (2011).
Pietrak, B. et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of alphaHG. Biochemistry 50, 4804–4812 (2011).
Savitski, M.M. et al. Targeted data acquisition for improved reproducibility and robustness of proteomic mass spectrometry assays. J. Am. Soc. Mass Spectrom. 21, 1668–1679 (2010).
Savitski, M.M. et al. Delayed fragmentation and optimized isolation width settings for improvement of protein identification and accuracy of isobaric mass tag quantification on Orbitrap-type mass spectrometers. Anal. Chem. 83, 8959–8967 (2011).
Savitski, M.M. et al. Measuring and managing ratio compression for accurate iTRAQ/TMT quantification. J. Proteome Res. 12, 3586–3598 (2013).
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. A Stat. Soc. 57, 289–300 (1995).
McCabe, M.T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 109, 2989–2994 (2012).
Passegué, E., Wagers, A.J., Giuriato, S., Anderson, W.C. & Weissman, I.L. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. J. Exp. Med. 202, 1599–1611 (2005).
Roth, M. et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood 120, 386–394 (2012).
Will, B. et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 114, 3899–3908 (2009).
Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 120, 1290–1298 (2012).
Will, B. et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 120, 2076–2086 (2012).
Akalin, A. et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet. 8, e1002781 (2012).
Akalin, A. et al. methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol. 13, R87 (2012).
McLean, C.Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
Acknowledgements
We thank D. Sun of the Einstein Human Stem Cell FACS and Xenotransplantation facility (supported by NYSTEM grant C024172) and J. Chen, C.K. Sheridan and F. Garrett-Bakelman of the Weill Cornell Medical College Epigenomics Core, and the Albert Einstein College of Medicine Epigenomics Core for expert technical assistance and advice. Funding: this work was supported by the Albert Einstein Cancer Center Core Support grant (P30CA013330), NYSTEM grant no. 24306 and GlaxoSmithKline (GSK). E.P. is supported by US National Institutes of Health (NIH) U24CA114737 and U10CA180827. U.C.O.-O. is supported by NIH F31CA162770 and the MSTP grant T32 GM007288. U.S. is a Research Scholar of the Leukemia & Lymphoma Society and is the Diane and Arthur B. Belfer Faculty Scholar in Cancer Research of the Albert Einstein College of Medicine.
Author information
Authors and Affiliations
Contributions
U.C.O.-O., B.B., B.W., M.T.M., N.D.A., A.V., B.S. and U.S. designed the study and experiments; U.C.O.-O., E.N.G., B.P., A.R.R., C.R., C.Q., A.S., K.J.W., A.J.R., S.J.S., H.Q., H.Z., G.J., M.F.-S., M.B., G.D., C.D., P.B., A.G., J.C., I.A.-D., K.M., L.C., M.T.M., N.D.A., P.B., B.S., H.R.W., H.M., Y.-R.K. and L.B. performed research and analyzed data; B.B. performed bioinformatic analysis; U.C.O.-O., I.A.-D., K.M. and S.-R.N. conducted in vivo studies; U.C.O.-O., B.B., B.W., M.C., E.P., H.M., N.C., N.D.A., B.S., M.T.M., J.M., A.V. and U.S. interpreted experiments and directed the study; and U.C.O.-O., N.D.A., B.S., M.T.M. and U.S. wrote the manuscript. All authors discussed results and contributed to the writing and editing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
This work was supported by GlaxoSmithKline (GSK), of which E.N.G., B.P., A.R.R., C.R., C.Q., A.S., K.J.W., A.J.R., S.J.S., H.Q., H.Z., G.J., M.F.-S., M.B., G.D., C.D., P.B., A.G., N.C., N.D.A., B.S. and M.T.M. are employees.
Supplementary information
Supplementary Text and Figures
Supplementary Results, Supplementary Tables 1–11, Supplementary Figures 1–7 and Supplementary Notes. (PDF 3010 kb)
Supplementary Data Set 1
Chemoproteomic approach showing selectivity of GSK321 for IDH1 [QUP, quantified unique peptides] (PDF 524 kb)
Supplementary Data Set 2
Differentially expressed genes by microarray analysis (PDF 249 kb)
Rights and permissions
About this article
Cite this article
Okoye-Okafor, U., Bartholdy, B., Cartier, J. et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol 11, 878–886 (2015). https://doi.org/10.1038/nchembio.1930
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1930
This article is cited by
-
Therapies for IDH-Mutant Gliomas
Current Neurology and Neuroscience Reports (2023)
-
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Journal of Experimental & Clinical Cancer Research (2022)
-
Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma
BMC Medical Genomics (2022)
-
Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
Nature Communications (2022)
-
Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
Oncogene (2022)